mProX™ Human TGFBR2 Stable Cell Line
- Product Category:
- Membrane Protein Stable Cell Lines
- Subcategory:
- Kinase Cell Lines
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number
Made to Order Inquiry
InquiryProduct Information
Product Properties
Protocols
Please visit our protocols page.
Customer Reviews
There are currently no Customer reviews or questions for mProX™ Human TGFBR2 Stable Cell Line (S01YF-1023-PY113). Click the button above to contact us or submit your feedback about this product.
Casey Davis (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Peyton Garcia (Verified Customer)
Patrick Liam (Creative Biolabs Scientific Support)
Published Data
Fig.1 The inhibition of CC cell proliferation was achieved through the overexpression of TGFBR2.
Following transfection with pcDNA3.1-TGFBR2, the cell proliferation rates of Ca Ski and SiHa cells were analyzed via CCK-8 assay.
Ref: Yuan, Jialing, Ke Yi, and Lingyun Yang. "TGFBR2 regulates hedgehog pathway and cervical cancer cell proliferation and migration by mediating SMAD4." Journal of proteome research 19.8 (2020): 3377-3385.
Pubmed: 32628850
DOI: 10.1021/acs.jproteome.0c00239
Research Highlights
Siljamäki, Elina. et al. "Inhibition of TGF-β signaling, invasion, and growth of cutaneous squamous cell carcinoma by PLX8394." Oncogene, 2023.
Cutaneous squamous cell carcinoma (cSCC) represents a prevalent metastatic skin cancer with poor patient prognoses, necessitating novel treatments. Prior research unveiled the impact of Ras/MEK/ERK1/2 and transforming growth factor β (TGF-β)/Smad2 signaling on laminin-332 accumulation and invasion in cSCC cells. In this study, it is demonstrated that the next-generation B-Raf inhibitor PLX8394 effectively impedes TGF-β signaling in ras-transformed metastatic epidermal keratinocytes (RT3 cells) with wild-type B-Raf and hyperactive Ras. PLX8394 effectively reduced phosphorylation of TGF-β receptor II, Smad2, p38 activity, MMP-1, MMP-13 synthesis, and laminin-332 buildup. Furthermore, it significantly curtailed the growth of human cSCC tumors and collagen degradation in an in vivo xenograft model. These findings suggest that PLX8394 exhibits potential as a therapeutic agent for advanced human cSCC.
Siljamäki, Elina. et al. "Inhibition of TGF-β signaling, invasion, and growth of cutaneous squamous cell carcinoma by PLX8394." Oncogene, 2023.
Pubmed:
37864034
DOI:
10.1038/s41388-023-02863-8
Elgun, Tugba. et al. "Effect of Aza-BODIPY-Photodynamic Therapy on The Expression of Carcinoma-Associated Genes and Cell Death Mode." Photodiagnosis and photodynamic therapy, 2023.
Breast cancer is a prevalent form of cancer among women worldwide. Photodynamic therapy (PDT) has emerged as a promising approach for treating cancer due to its targeted and low cytotoxicity to healthy cells and tissues. Aza-BODIPY, a light-sensitive agent, has shown potential as a photosensitizer for use in PDT. Our research has demonstrated that aza-BODIPY-PDT can induce apoptosis in MCF-7 cells, likely through the involvement of p53 and caspase3. Further investigations are needed to elucidate the molecular pathways underlying aza-BODIPY-PDT-induced cell death, in order to enhance the effectiveness of this technique for breast cancer treatment.
Elgun, Tugba. et al. "Effect of Aza-BODIPY-Photodynamic Therapy on The Expression of Carcinoma-Associated Genes and Cell Death Mode." Photodiagnosis and photodynamic therapy, 2023.
Pubmed:
37863378
DOI:
10.1016/j.pdpdt.2023.103849
